<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062385</url>
  </required_header>
  <id_info>
    <org_study_id>V260-024</org_study_id>
    <nct_id>NCT02062385</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy, safety, and immunogenicity of a 3-dose regimen of
      RotaTeq™ (V260) in healthy Chinese infants. Approximately 4040 participants at least 6 weeks
      and up to 12 weeks of age at the time of the first vaccination with V260 or placebo will be
      enrolled and randomized (1:1) to receive either V260 or placebo. Participants will also
      receive the routine China Expanded Program on Immunization (EPI) vaccines (oral poliovirus
      vaccine [OPV] and diphtheria, tetanus, and acellular pertussis vaccine [DTaP]) either
      staggered or concomitantly with V260 or placebo. All participants will be followed for
      efficacy and safety. Immune responses to OPV and DTaP will be evaluated in a subset of
      participants. The primary hypothesis of the study states that V260 will be efficacious in
      preventing any severity of rotavirus gastroenteritis as compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2014</start_date>
  <completion_date type="Actual">June 11, 2015</completion_date>
  <primary_completion_date type="Actual">June 11, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Severity of Rotavirus Gastroenteritis</measure>
    <time_frame>From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)</time_frame>
    <description>The number of participants with rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Elevated Temperature</measure>
    <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
    <description>Elevated temperature (temperature &gt;=37.5°C axillary or equivalent) was noted by the guardian and recorded on the Vaccination Report Card during Day 1 to Day 14 after each dose of vaccination. Elevated temperature reported by the guardian was also collected as an adverse event (pyrexia) during Day 15 to Day 30 after each dose of vaccination. The percentage of participants with axillary temperature &gt;=37.5 °C or an adverse event of pyrexia was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Vomiting or Diarrhea</measure>
    <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
    <description>Episodes of vomiting and diarrhea were noted by the guardian and recorded on the Vaccination Record Card during Day 1 to Day 14 after each dose of vaccination. Vomiting and diarrhea reported by the guardian were also collected as an adverse event during Day 15 to Day 30 after any dose of vaccination. The percentage of participants with an episode or an adverse event of vomiting or diarrhea was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Intussusception</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Episodes of intussusception were collected from the time of written consent until the end of study. The percentage of participants with an episode of intussusception was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Rotavirus Gastroenteritis</measure>
    <time_frame>From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)</time_frame>
    <description>The number of participants with severe rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. Severe RVGE was defined as &gt;=11 on the Vesikari Scoring System, a composite of the seven parameters related to symptoms and treatment with an overall range from 0 to 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3</measure>
    <time_frame>Baseline and between 28 and 56 days after the third OPV vaccination</time_frame>
    <description>The percentage of participants who achieved seroprotection against poliovirus Type 1, 2, or 3 was assessed. Seroprotection was defined as a neutralizing antibody titer &gt;=1:8. This outcome was evaluated only in participants receiving concomitant administration of V260 and OPV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Adverse Event</measure>
    <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the sponsor's product, is also an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Seropositive to Diphtheria, Pertussis, or Tetanus Antigens</measure>
    <time_frame>Baseline and between 28 and 51 days after the third DTaP vaccination</time_frame>
    <description>The percentage of participants seropositive to diphtheria, pertussis, or tetanus antigens was assessed. Seropositive was defined as the following: 1) anti-diphtheria antibody titers &gt;=0.1 International Units (IU)/mL, 2) anti-tetanus antibody titers &gt;=0.1 IU/mL, 3) antipertussis toxin antibody titers &gt;=20 Enzyme-linked Immunosorbent Assay (ELISA) Units (EU)/mL, 4) anti-pertussis filamentous hemagglutinin (FHA) antibody titers &gt;=20 EU/mL. This outcome was evaluated only in participants receiving concomitant administration of V260 and EPI.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4040</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>V260 with staggered EPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with staggered EPI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V260 with concomitant EPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with concomitant EPI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V260</intervention_name>
    <description>V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)</description>
    <arm_group_label>V260 with staggered EPI</arm_group_label>
    <arm_group_label>V260 with concomitant EPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo to V260</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo with staggered EPI</arm_group_label>
    <arm_group_label>Placebo with concomitant EPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OPV</intervention_name>
    <description>Oral poliovirus vaccine administered according to the standard of care</description>
    <arm_group_label>V260 with staggered EPI</arm_group_label>
    <arm_group_label>Placebo with staggered EPI</arm_group_label>
    <arm_group_label>V260 with concomitant EPI</arm_group_label>
    <arm_group_label>Placebo with concomitant EPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP</intervention_name>
    <description>Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care</description>
    <arm_group_label>V260 with staggered EPI</arm_group_label>
    <arm_group_label>Placebo with staggered EPI</arm_group_label>
    <arm_group_label>V260 with concomitant EPI</arm_group_label>
    <arm_group_label>Placebo with concomitant EPI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants at least 6 weeks (42 days) and up to 12 weeks (84 days) of age at the
             time of the first study vaccination

          -  Parent/legal guardian agrees to participate by giving written informed consent and is
             willing and able to comply with study requirements

        Exclusion Criteria:

          -  History of congenital abdominal disorders, prior rotavirus gastroenteritis, chronic
             diarrhea, failure to thrive, or abdominal surgery

          -  History of intussusception

          -  Impairment of immunological function, including Severe Combined Immunodeficiency
             (SCID)

          -  Acute disease, severe chronic disease, or chronic disease during the acute period

          -  Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological
             disease

          -  Hypersensitivity to any component of the rotavirus vaccine, OPV, or DTaP

          -  Prior receipt of any rotavirus vaccine

          -  Fever, with an axillary temperature &gt;=37.5 °C (or equivalent) within 24 hours before
             study vaccination (study vaccination can be deferred until complete resolution of
             febrile illness)

          -  Clinical evidence of active gastrointestinal illness

          -  Received intramuscular, oral, or intravenous corticosteroid treatment since birth
             (topical, ophthalmic, and inhaled steroids are permitted)

          -  Resides in a household with an immunocompromised person

          -  Receipt of a blood transfusion or blood products, including immunoglobulins

          -  Participation in another interventional study within 14 days before the first study
             vaccination or during the study

          -  Receipt of an investigational or non-registered product other than the study vaccine
             within 30 days before the first study vaccination or during the study

          -  For participants in immunogenicity arms: inability to obtain a blood specimen at
             randomization visit (note: the visit may be rescheduled so that a baseline specimen
             may be obtained); history of polio, diphtheria, tetanus, or pertussis disease;
             previous vaccination against diphtheria, tetanus, pertussis, or poliomyelitis

          -  Any condition which, in the opinion of the investigator, may interfere with the
             evaluation of the study objectives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <results_reference>
    <citation>Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, Wei D, Fu B, Liao X, Chu J, Qiu Y, Hille DA, Nelson M, Kaplan SS. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: A randomized, double-blind, placebo-controlled trial. Vaccine. 2017 Oct 13;35(43):5897-5904. doi: 10.1016/j.vaccine.2017.08.081. Epub 2017 Sep 19.</citation>
    <PMID>28935470</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 4173 participants were screened, 4040 were randomized, and 4037 received at least one dose of study vaccination.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V260 With Staggered EPI</title>
          <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunization (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo With Staggered EPI</title>
          <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months.</description>
        </group>
        <group group_id="P3">
          <title>V260 With Concomitant EPI</title>
          <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
        <group group_id="P4">
          <title>Placebo With Concomitant EPI</title>
          <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1620"/>
                <participants group_id="P2" count="1620"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="1618"/>
                <participants group_id="P2" count="1619"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="400"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="1554"/>
                <participants group_id="P2" count="1566"/>
                <participants group_id="P3" count="392"/>
                <participants group_id="P4" count="393"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="1543"/>
                <participants group_id="P2" count="1554"/>
                <participants group_id="P3" count="389"/>
                <participants group_id="P4" count="392"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1542"/>
                <participants group_id="P2" count="1555"/>
                <participants group_id="P3" count="388"/>
                <participants group_id="P4" count="391"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete EPI by database lock</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>V260 With Staggered EPI</title>
          <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo With Staggered EPI</title>
          <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months.</description>
        </group>
        <group group_id="B3">
          <title>V260 With Concomitant EPI</title>
          <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
        <group group_id="B4">
          <title>Placebo With Concomitant EPI</title>
          <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1620"/>
            <count group_id="B2" value="1620"/>
            <count group_id="B3" value="400"/>
            <count group_id="B4" value="400"/>
            <count group_id="B5" value="4040"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="10.0"/>
                    <measurement group_id="B2" value="57.2" spread="9.7"/>
                    <measurement group_id="B3" value="68.3" spread="5.7"/>
                    <measurement group_id="B4" value="68.5" spread="5.7"/>
                    <measurement group_id="B5" value="59.5" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="806"/>
                    <measurement group_id="B2" value="775"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="183"/>
                    <measurement group_id="B5" value="1949"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="845"/>
                    <measurement group_id="B3" value="215"/>
                    <measurement group_id="B4" value="217"/>
                    <measurement group_id="B5" value="2091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Severity of Rotavirus Gastroenteritis</title>
        <description>The number of participants with rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms.</description>
        <time_frame>From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)</time_frame>
        <population>Participants who were vaccinated in either the staggered EPI or concomitant EPI groups, were not protocol violators, and were classified as evaluable for RVGE according to the per-protocol case definition.</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Severity of Rotavirus Gastroenteritis</title>
          <description>The number of participants with rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms.</description>
          <population>Participants who were vaccinated in either the staggered EPI or concomitant EPI groups, were not protocol violators, and were classified as evaluable for RVGE according to the per-protocol case definition.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1927"/>
                <count group_id="O2" value="1937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>V260 will be considered efficacious if the lower bound of the two-sided confidence interval for efficacy is &gt;0% at the final analysis</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Clopper-Pearson</method>
            <method_desc>To calculate the confidence interval and associated p-value, an exact conditional method based on a Poisson distribution was used.</method_desc>
            <param_type>1 - (Incidence V260 / Incidence Placebo)</param_type>
            <param_value>69.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.5</ci_lower_limit>
            <ci_upper_limit>79.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Elevated Temperature</title>
        <description>Elevated temperature (temperature &gt;=37.5°C axillary or equivalent) was noted by the guardian and recorded on the Vaccination Report Card during Day 1 to Day 14 after each dose of vaccination. Elevated temperature reported by the guardian was also collected as an adverse event (pyrexia) during Day 15 to Day 30 after each dose of vaccination. The percentage of participants with axillary temperature &gt;=37.5 °C or an adverse event of pyrexia was assessed.</description>
        <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
        <population>All Subjects as Treated with follow-up specific to the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Temperature</title>
          <description>Elevated temperature (temperature &gt;=37.5°C axillary or equivalent) was noted by the guardian and recorded on the Vaccination Report Card during Day 1 to Day 14 after each dose of vaccination. Elevated temperature reported by the guardian was also collected as an adverse event (pyrexia) during Day 15 to Day 30 after each dose of vaccination. The percentage of participants with axillary temperature &gt;=37.5 °C or an adverse event of pyrexia was assessed.</description>
          <population>All Subjects as Treated with follow-up specific to the endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="2019"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.84"/>
                    <measurement group_id="O2" value="22.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Vomiting or Diarrhea</title>
        <description>Episodes of vomiting and diarrhea were noted by the guardian and recorded on the Vaccination Record Card during Day 1 to Day 14 after each dose of vaccination. Vomiting and diarrhea reported by the guardian were also collected as an adverse event during Day 15 to Day 30 after any dose of vaccination. The percentage of participants with an episode or an adverse event of vomiting or diarrhea was assessed.</description>
        <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
        <population>All Subjects as Treated with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Vomiting or Diarrhea</title>
          <description>Episodes of vomiting and diarrhea were noted by the guardian and recorded on the Vaccination Record Card during Day 1 to Day 14 after each dose of vaccination. Vomiting and diarrhea reported by the guardian were also collected as an adverse event during Day 15 to Day 30 after any dose of vaccination. The percentage of participants with an episode or an adverse event of vomiting or diarrhea was assessed.</description>
          <population>All Subjects as Treated with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="2019"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68"/>
                    <measurement group_id="O2" value="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.15"/>
                    <measurement group_id="O2" value="20.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Intussusception</title>
        <description>Episodes of intussusception were collected from the time of written consent until the end of study. The percentage of participants with an episode of intussusception was assessed.</description>
        <time_frame>Up to 15 months</time_frame>
        <population>All Subjects as Treated with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intussusception</title>
          <description>Episodes of intussusception were collected from the time of written consent until the end of study. The percentage of participants with an episode of intussusception was assessed.</description>
          <population>All Subjects as Treated with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="2019"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10"/>
                    <measurement group_id="O2" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Rotavirus Gastroenteritis</title>
        <description>The number of participants with severe rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. Severe RVGE was defined as &gt;=11 on the Vesikari Scoring System, a composite of the seven parameters related to symptoms and treatment with an overall range from 0 to 20.</description>
        <time_frame>From 14 days after the third dose of V260 or placebo through the first rotavirus season (up to 15 months)</time_frame>
        <population>Participants who were vaccinated in either the staggered EPI or concomitant EPI groups, were not protocol violators, and were classified as evaluable for RVGE according to the per-protocol case definition.</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Rotavirus Gastroenteritis</title>
          <description>The number of participants with severe rotavirus gastroenteritis (RVGE) caused by naturally-occurring wild-type rotavirus (regardless of serotype or disease severity) was assessed. The case definition of RVGE included 1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and 2) naturally-occurring wild-type rotavirus must be detected in a stool specimen taken within 7 days after the onset of symptoms. Severe RVGE was defined as &gt;=11 on the Vesikari Scoring System, a composite of the seven parameters related to symptoms and treatment with an overall range from 0 to 20.</description>
          <population>Participants who were vaccinated in either the staggered EPI or concomitant EPI groups, were not protocol violators, and were classified as evaluable for RVGE according to the per-protocol case definition.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1926"/>
                <count group_id="O2" value="1937"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3</title>
        <description>The percentage of participants who achieved seroprotection against poliovirus Type 1, 2, or 3 was assessed. Seroprotection was defined as a neutralizing antibody titer &gt;=1:8. This outcome was evaluated only in participants receiving concomitant administration of V260 and OPV.</description>
        <time_frame>Baseline and between 28 and 56 days after the third OPV vaccination</time_frame>
        <population>Participants in the concomitant EPI groups who receive their scheduled doses of OPV without intervening disease specific to the antigen before the blood sample collection postdose 3, adhere to the guidelines for administration of vaccine, and have valid values available for analysis within specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Seroprotection Against Poliovirus Type 1, 2, or 3</title>
          <description>The percentage of participants who achieved seroprotection against poliovirus Type 1, 2, or 3 was assessed. Seroprotection was defined as a neutralizing antibody titer &gt;=1:8. This outcome was evaluated only in participants receiving concomitant administration of V260 and OPV.</description>
          <population>Participants in the concomitant EPI groups who receive their scheduled doses of OPV without intervening disease specific to the antigen before the blood sample collection postdose 3, adhere to the guidelines for administration of vaccine, and have valid values available for analysis within specified day ranges.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poliovirus Type 1: Baseline, n=186, 190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.09" lower_limit="36.83" upper_limit="51.54"/>
                    <measurement group_id="O2" value="38.95" lower_limit="31.97" upper_limit="46.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 1: Post OPV #3, n=187, 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.93" lower_limit="96.19" upper_limit="99.87"/>
                    <measurement group_id="O2" value="100.00" lower_limit="98.10" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 2: Baseline, n=186, 190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.09" lower_limit="36.83" upper_limit="51.54"/>
                    <measurement group_id="O2" value="41.58" lower_limit="34.49" upper_limit="48.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 2: Post OPV #3, n=187, 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="98.05" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="98.10" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 3: Baseline, n=186, 190</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.27" lower_limit="19.20" upper_limit="32.15"/>
                    <measurement group_id="O2" value="21.05" lower_limit="15.49" upper_limit="27.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus Type 3: Post OPV #3, n=187, 192</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.93" lower_limit="96.19" upper_limit="99.87"/>
                    <measurement group_id="O2" value="98.96" lower_limit="96.29" upper_limit="99.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Adverse Event</title>
        <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the sponsor’s product, is also an adverse event.</description>
        <time_frame>Up to 30 days after any dose of V260 or Placebo</time_frame>
        <population>All Subjects as Treated with safety follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Staggered or Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Staggered or Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event</title>
          <description>An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the sponsor’s product, is also an adverse event.</description>
          <population>All Subjects as Treated with safety follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2015"/>
                <count group_id="O2" value="2019"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Seropositive to Diphtheria, Pertussis, or Tetanus Antigens</title>
        <description>The percentage of participants seropositive to diphtheria, pertussis, or tetanus antigens was assessed. Seropositive was defined as the following: 1) anti-diphtheria antibody titers &gt;=0.1 International Units (IU)/mL, 2) anti-tetanus antibody titers &gt;=0.1 IU/mL, 3) antipertussis toxin antibody titers &gt;=20 Enzyme-linked Immunosorbent Assay (ELISA) Units (EU)/mL, 4) anti-pertussis filamentous hemagglutinin (FHA) antibody titers &gt;=20 EU/mL. This outcome was evaluated only in participants receiving concomitant administration of V260 and EPI.</description>
        <time_frame>Baseline and between 28 and 51 days after the third DTaP vaccination</time_frame>
        <population>Participants in the concomitant EPI groups who receive their scheduled doses of DTaP without intervening disease specific to the antigen before the blood sample collection postdose 3, adhere to the guidelines for administration of vaccine, and have valid values available for analysis within specified day ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>V260 With Concomitant EPI</title>
            <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo With Concomitant EPI</title>
            <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Seropositive to Diphtheria, Pertussis, or Tetanus Antigens</title>
          <description>The percentage of participants seropositive to diphtheria, pertussis, or tetanus antigens was assessed. Seropositive was defined as the following: 1) anti-diphtheria antibody titers &gt;=0.1 International Units (IU)/mL, 2) anti-tetanus antibody titers &gt;=0.1 IU/mL, 3) antipertussis toxin antibody titers &gt;=20 Enzyme-linked Immunosorbent Assay (ELISA) Units (EU)/mL, 4) anti-pertussis filamentous hemagglutinin (FHA) antibody titers &gt;=20 EU/mL. This outcome was evaluated only in participants receiving concomitant administration of V260 and EPI.</description>
          <population>Participants in the concomitant EPI groups who receive their scheduled doses of DTaP without intervening disease specific to the antigen before the blood sample collection postdose 3, adhere to the guidelines for administration of vaccine, and have valid values available for analysis within specified day ranges.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria: Baseline, n=181, 186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="1.23" upper_limit="7.08"/>
                    <measurement group_id="O2" value="2.69" lower_limit="0.88" upper_limit="6.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria: Post DTaP #3, n=187, 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.47" lower_limit="97.06" upper_limit="99.99"/>
                    <measurement group_id="O2" value="99.48" lower_limit="97.16" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA: Baseline, n=181, 186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis FHA: Post DTaP #3, n=187, 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.92" lower_limit="37.65" upper_limit="52.35"/>
                    <measurement group_id="O2" value="43.81" lower_limit="36.72" upper_limit="51.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis Toxin: Baseline, n=181, 186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" lower_limit="0.34" upper_limit="4.77"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.13" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis Toxin, Post DTaP #3, n=187, 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.19" lower_limit="91.06" upper_limit="97.78"/>
                    <measurement group_id="O2" value="94.33" lower_limit="90.08" upper_limit="97.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Baseline, n=181, 186</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.15" lower_limit="7.78" upper_limit="17.82"/>
                    <measurement group_id="O2" value="12.37" lower_limit="8.00" upper_limit="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus: Post DTaP #3, n=187, 194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="98.05" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="98.12" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events: up to 30 days after any V260 or placebo vaccination; Serious Adverse Events: from the time of written consent until the end of the study (up to 15 months)</time_frame>
      <desc>The at-risk population was All Subjects as Treated</desc>
      <group_list>
        <group group_id="E1">
          <title>V260 With Staggered or Concomitant EPI</title>
          <description>V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo With Staggered or Concomitant EPI</title>
          <description>Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months OR concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="339" subjects_at_risk="2015"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Thalassaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Thalassaemia beta</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="2015"/>
                <counts group_id="E2" events="42" subjects_affected="41" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient hypogammaglobulinaemia of infancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2015"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="89" subjects_affected="84" subjects_at_risk="2015"/>
                <counts group_id="E2" events="108" subjects_affected="101" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="144" subjects_affected="129" subjects_at_risk="2015"/>
                <counts group_id="E2" events="158" subjects_affected="141" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="2015"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2015"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2015"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="2015"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2015"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="2015"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="30" subjects_at_risk="2015"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2015"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="2015"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rickets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2015"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2015"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2015"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="938" subjects_at_risk="2015"/>
                <counts group_id="E2" subjects_affected="931" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="487" subjects_affected="406" subjects_at_risk="2015"/>
                <counts group_id="E2" events="504" subjects_affected="406" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="492" subjects_affected="414" subjects_at_risk="2015"/>
                <counts group_id="E2" events="481" subjects_affected="419" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="248" subjects_affected="228" subjects_at_risk="2015"/>
                <counts group_id="E2" events="268" subjects_affected="233" subjects_at_risk="2019"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="98" subjects_affected="91" subjects_at_risk="2015"/>
                <counts group_id="E2" events="114" subjects_affected="103" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="133" subjects_affected="115" subjects_at_risk="2015"/>
                <counts group_id="E2" events="109" subjects_affected="92" subjects_at_risk="2019"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

